Search PubMed⌕ Search

Biomedical subjects

B Woggon

Publications and source records attributed to B Woggon.

At least 73 records · Page 4Linked to original sources
PubMed1979

[Influence of diagnosis and length of hospitalization on the retest reliability for findings of the first psychopathological test (AMP system)].

80 inpatients were interviewed twice by the same physician with an interval of 24 h. By forming subgroups concerning diagnosis and duration of hospitalization, it was possible to examine the influence of these two criteria on the retest reliability of the following findings: (1) aspects of the interview; (2) AMP symptoms; (3) AMP syndromes; (4) clinical syndrome diagnoses, and (5) nosological diagnoses. The duration of hospitalization (up to 40 days) had no influence on the retest reliability of the described findings. The diagnosis (schizophrenia/depression) had no influence on the well-structured findings (AMP symptoms, AMP syndromes). On the contrary, the diagnosis influenced findings which are not so well structured and defined (aspects of the interview, clinical syndrome diagnoses, nosological diagnoses).

Adolescent↗
PubMed1979

[Examination of the retest reliability of the findings of the first psychopathological examination (AMP system)].

80 inpatients were interviewed two times by the same rate during 24 h. Using Kappa, the retest reliability of the following parts of the psychopathological findings was determined: (1) aspects of the interview (median 0.54); (2) AMP symptoms (median 0.72); (3) AMP syndromes (median 0.79); (4) clinical syndromes (median 0.77), and (5) nosologic diagnoses (median 0.93). Based on structured rating of the psychopathological symptoms, a good retest reliability was found.

Adolescent↗
PubMed1979

[Reproducibility of the factorial structure of the AMP system].

Using the data of 552 patients mainly suffering from endogenous psychoses, the factorial structure (2--9 factors) of the AMP system was determined and compared to the results of a previous analysis. The 2- to 5-factor solutions were reproduced. In the 9-factor solution, on which the 9 known AMP scales are based, 2 factors ('paranoid' and 'hypochondriac syndrome') were not completely reproducible.

Humans↗
PubMed1979

[Construction of second order AMP scales: "manic depressives" and "schizophrenic syndrome"].

A previous two-factor solution of the AMP system was confirmed by a factor analysis in 552 patients, mainly suffering from endogenous psychoses. Based on these results, two second-order scales ('manic-depressive' and 'schizophrenic syndrome') were constructed according to the classical theory of mental testing. The scales are orthogonal. Their reliability and validity is satisfactory. It is suggested to use the two new scales together with the known 9 AMP scales.

Behavior↗
PubMed1978

[Interrater reliability of amp symptoms (author's transl)].

Two psychiatrists examined 48 patients (25 depressed and 23 schizophrenic). Each documented the symptoms on AMP sheets 3 (psychopathologic symptoms) and 4 (somatic signs, first column only). The study deals with 139 AMP symptoms. Seventy could be judged concerning symptom exists/does not exist. Of these 70 symptoms, 45 showed a good or moderate interrater reliability. Specific symptoms had a better reliability than nonspecific. Symptoms described by the patients had a better reliability than those judged by the doctor alone. The results indicate that expanded use of the AMP system in its present form is problematic. Work on a new version of the AMP system has already begun.

Anxiety↗
PubMed1978

Double-blind comparison of bromperidol and perphenazine.

Within the scope of a clinical double-blind study, effects and side effects of Bromperidol and Perphenazine were compared. Forty newly-hospitalized schizophrenic patients were included in the trial. Assessments were made on days 0, 2, 5, 10, 20, and 30. Data were documented by means of the AMP system, the EPRS scale of Simpson and Angus, and a Brief Ward Behaviour Rating Scale. Laboratory tests and ECGs were performed before and after treatment. Treatment was scheduled for 30 days and dosages were established depending on effects and side effects. We found a therapeutic effective mean daily dose of 6 mg for Bromperidol and 20 mg for Perphenazine. Both substances caused autonomic and extrapyramidal side effects and, in a few patients, temproary fatigue. The employed dosage caused no strong sedation. To sum up, Bromperidol and Perphenazine can be described as highly potent and well tolerated antipsychotic drugs. We observed stronger efficacy and earlier onset of action with Bromperidol. The superior effect of Bromperidol cannot be explained by a higher dosage as compared with Perphenazine, since both substances showed a similar severity of extrapyramidal side effects, and the dosage of both substances was established individually for each patient, depending on effects and side effects.

Adult↗
PubMed1978

[Penfluridol. Results of a year-long clinical trial].

During an open clinical trial, 51 schizophrenic patients were treated with Penfluirdol, 34 for 1 year and 17 for a shorter time. The mean dosage of Penfluirdol was 22 up to 28 mg per week. Assessments were made on days 0, 14, 28, 56, 90, 180, 270, and 365 using the AMP system and the EPRS scale of Simpson and Angus. The symptomatology was mainly reduced during the first 3 months of treatment and remained afterwards relative unchanged. Penfluridol showed a good antipsychotic effect on productive schizophrenic symptoms (thought disorders and paranoid symptoms, autism and schizophrenic affective disorders). The dosage used showed only a slight sedative effect and was well tolerated concerning autonomic and extrapyramidal side-effects.

Adult↗
PubMed1977

The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study.

In the last few years several open studies supported the hypothesis that L-5-HTP may be an effective antidepressant. Because of the lack of a controlled double-blind trial we started our own investigations to confirm this hypothesis in L-5-HTP. In 1972 we performed two open dose finding trials with L-5-HTP in combination with Benzerazide. These open studies were followed by a double-blind trial comparing L-5-HTP in combination with Benzerazide to Imipramine in 30 patients. Assessments were carried out on day 0, 5, 10, 15 and 20. For data collection we used the Hamilton Rating Scale for Depression, the AMP-system, a Global Rating Scale of Severity of Depression and a Brief Rating Scale for the Behaviour on the ward. In this article we report only a part of the results, mainly on the findings with the AMP-system and the Hamilton Rating Scale for Depression. During our double-blind trial we could not find any significant difference in efficacy of L-5-HTP and Imipramine. The same was found in an open trial. Furthermore the L-5-HTP results showed no difference compared with the results of an Imipramine treatment in 40 patients in earlier double-blind studies. L-5-HTP and Imipramine caused different patterns of side effects. L-5-HTP caused mainly gastrointestinal side effects and Imipramine caused mainly dryness of the mouth and tremor. The gastrointestinal side effects caused by L-5-HTP seemed to be dose dependent.

5-Hydroxytryptophan↗
PubMed1977

[Difficulties of a clinician in planning psychopharmacological trials (author's transl)].

From the clinical examinators point of view, we present a few problems in planning psychopharmacological trials. Our main topic is not answering the questions but formulating them in a more precise manner. The following problems are discussed: formulation of hypotheses, choice of experimental designs (open, double-blind, placebo-controlled), effects of placebo, choice of reference substances, duration of trials, pharmacopsychiatric acute trials, frequence and interval of assessments, size and kind of patient sample, fixed or flexible dosage schedule, pretreatment, wash-out, additional medication, choice of the assessement instrument and double assessment of the initial values.

Clinical Trials as Topic↗
PubMed1977

Open trial and double-blind clinical trial of the antidepressant Ro 8-1998 in comparison with imipramine.

Based on the results of an open trial with Ro 8-1998 (chemic name: N,N-dimethyl-3-(1-methyl-5H-dibenzo(a,d)cycloheptene-5-ylidene)-propylamine N-oxide hydrochloride) in 11 endogenous depressed outpatients a double-blind trial with imipramine was proposed. Therapeutic efficacy and side effects of Ro 8-1998 and imipramine were compared in a double-blind trial with 30 patients who were newly hospitalized. Most of them suffered from endogenous depression. On days 0, 5, 10, 15 and 20 the patients were examined and the symptoms were documented with the AMP system, the Hamilton scale for depression, a behaviour rating and the "global depression rating Zurich". Ro 8-1998 caused a decrease of systolic blood pressure, an increase of heart frequency and urea. Twelve out of 15 patients showed a decrease of white blood cells. In four patients the number of white blood cells dropped below 4,000. Statistical analyses proved both substances to be potent antidepressants. The therapeutic efficacy of Ro 8-1998 was at least equal to that of imipramine. Further trials with bigger groups of patients are necessary to show whether the trend towards a better antidepressant efficacy of Ro 8-1998 can be reproduced.

Adult↗
PubMed1977

Antipsychotic effects, side effects and effective dosis of the butyrophenone lenperone (AHR 2277).

Three open studies with Lenperone were performed. 50 hospitalized schizophrenic patients were treated 20-30 days with Lenperone. The therapeutic effective dose was 30-50 mg/day. The highest daily dosage was 90 mg. Patients were examined on fixed observation days and the findings were documented by means of the AMP system. AMP data were analyzed at symptom and syndrome level and compared using an analysis of covariance. In the described dosage Lenperone acted only little sedating, strong antipsychotic and caused only a few single extrapyramidal and little autonomic side effects. The dosage is limited because of the effect on heart and blood circulation. Lenperone caused a good improvement of depressive symptoms in the schizophrenic patients. Lenperone was well tolerated and slowed a rapid onset of its antipsychotic effect. It caused a steady improvement of productive schizophrenic symptoms. For better knowledge of the profile of the effects of Lenperone, a trial in depressive paranoid syndromes, for example schizoaffective psychoses, would be interesting; a double-blind trial in comparison to a well-known antipsychotic would be very useful.

Adult↗
PubMed1977

[Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].

Fluphenazine decanoate and pipothiazine palmitate were compared concerning their effect and side-effects. 61 schizophrenic patients were treated up to 6 months in a multicenter double-blind trial. Assessments were made on day 0 and after 5, 10, 17 and 22 weeks of treatment using the AMP system. Pipothiazine palmitate was injected every 4th week and fluphenazine decanoate every 3rd week. The most often applied dosage was 100 mg pipothiazine palmitate and 25 or 37.5 mg fluphenazine decanoate. Data analysis of the AMP system at the symptom level showed the better antipsychotic effect of pipothiazine palmitate. A comparison between the two groups by means of analysis of covariance at the syndrome level showed no statistical significant differences between the effects of fluphenazine decanoate and pipothiazine palmitate.

Antipsychotic Agents↗
PubMed1976

[Clinical double-blind study with two different dosages of maprotiline (150 and 225 mg per day) (author's transl)].

Effects and side-effects of 150 mg and 225 mg maprotiline per day were compared by means of a double-blind trial in 20 depressed inpatients. The first 2 days patients received a high initial dosage of 300 mg per day. Patients were examined on days 0, 2, 5, 10, 15, 20, and 30. Symptoms were evaluated by the AMP system and the Hamilton scale for depressions. Laboratory examinations were carried out on days 0, 10, 20, and 30. Exanthemas developed in five patients, three of whom were on the higher dosage. Moreover, the lower dosage caused less fine hand tremor. Coinciding with the beginning of treatment a linear decrease of depressive symptoms was noted. This demonstrates the rapid onset of the antidepressant effect. Moreover, contrary to what has been stated for antidepressants generally, the onset of action was frequently noted well before 10-20 days of treatment. Some patients improved within a few days while others needed more time. The time lag until antidepressants influence depressive symptoms shows pronounced individual differences. No significant difference between the two dosages was found. The profiles show a better antidepressant effect for the higher dosage; however, because of a higher incidence of side-effects on the higher dosage of maprotiline, it cannot be recommended as routine. On the other hand, depressive inpatients should receive a daily dosage of at least 150 mg. Our findings suggest a dose-effect relationship for maprotiline.

Adult↗
PubMed1976

[Activity profile of carpipramine. Results of an open trial and a double-blind trial versus doxepin].

During an uncontrolled trial 46 depressed patients (39 endogenous depressions, 5 schizoaffective psychoses and 2 paranoic schizophrenics with depressive syndromes) were treated for 43 days on the average with 3 X 100 mg 1-[3-(10,11-dihydro-5H-dibenz[b,f]-azepin-5-yl)-propyl]-4-piperidino-piperidine-4-carboxamide-dihydrochloride-monohydrate (carpipramine) daily. The clinical impression of the improvement and the results of the Hamilton-Scale for depressions (19 patients, 24 items) showed a clear antidepressive effect of carpipramine. During a double-blind trial 14 patients were treated with carpipramine and 16 with doxepine for 30 days. Most patients suffered from endogenous depressions with paranoic symptoms or from schizophrenia with depressive syndromes. Statistical analysis of the Hamilton-Scale for depressions and the AMP-System showed the antidepressive and antipsychotic effect of carpipramine. Analysis of covariance showed no significant difference between carpipramine and doxepine. Altogether we treated 60 depressive patients with carpipramine. 26 patients improved very well and 11 moderately, that means 37 patients out of 60 reacted positively to therapy with carpipramine. One endogenous depression and a schizoaffective psychosis changed into a manic phase. A provocation of schizophrenic symptoms was not noticed. Carpipramine was very well tolerated and can be classified as a non-sedative antidepressant with an antipsychotic effect.

Anti-Anxiety Agents↗